TAL, an Australian subsidiary of the Dai-ichi Life Group, has proposed acquiring Australian major life insurer Challenger. The purchase price is expected to be approximately ¥700 billion. The proposal is described as a non-binding, early-stage offer, and Challenger's board is expected to consider it.
TAL, the Australian subsidiary of the Dai-ichi Life Group, has made an acquisition proposal for Challenger. Dai-ichi Life currently holds approximately 20% of Challenger's shares.
The proposal envisages acquiring the remaining approximately 80% of the shares through TAL, with the acquisition expected to be valued at approximately ¥700 billion. The move is aimed at expanding earnings in the Australian market.
Challenger mainly provides annuity insurance for individuals. Against the backdrop of a shrinking insurance market in Japan, Dai-ichi Life is believed to be pursuing continued growth in the Australian market.
The proposal is an initial, non-binding one, and Challenger's board is reviewing its terms. Dai-ichi Life has commented that it has not decided at this point to proceed with a legally binding transaction.